ConductScience.org, home

Paper57791

The effect of bleomycin and pentamycin in combination on the survival of EMT6 mouse tumour cells in vitro and in vivo.

Twentyman PR. Br J Cancer, 1976. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. The effect of bleomycin and pentamycin in combination on the survival of EMT6 mouse tumour cells in vitro and in vivo. Papers, record 57791. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/57791

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The effect of bleomycin and pentamycin in combination on the survival of EMT6 mouse tumour cells in vitro and in vivo.
PubMed
Journal
Br J Cancer
PubMed
Year
1976
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.41
iCite
Revised in PubMed
2019-12-10
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Twentyman PRP R

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antifungal AgentsMajor topic
BleomycinMajor topic
Cell SurvivalMajor topic
Animals
Cell Line
Cell Membrane
Dose-Response Relationship, Drug
Drug Synergism
In Vitro Techniques
Macrolides
Mice
Neoplasms, Experimental
Polyenes
Time Factors

Source PubMed

Download CSV of topics

References6

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14138662Radioautographic studies on the intracellular distribution of bleomycin-14C in mouse tumor cells.Cancer Res1974https://conductscience.org/library/papers/4138662PubMed
24138969Potentiation of bleomycin by an antifungal polyene, pentamycin, in transformed animal cells.Cancer Res1974https://conductscience.org/library/papers/4138969PubMed
34143273The sensitivity to bleomycin of a solid mouse tumour at different stages of growth.Br J Cancer1974https://conductscience.org/library/papers/4143273PubMed
44823906Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia.Cancer Res1974https://conductscience.org/library/papers/4823906PubMed
54121070Effect of bleomycin on mammalian cell survival.J Natl Cancer Inst1972https://conductscience.org/library/papers/4121070PubMed
64133497Potentiation of 5-fluorouracil, chromomycin A3, and bleomycin by amphotericin B or polymyxin B in transformed fibroblastic cells.Antimicrob Agents Chemother1973https://conductscience.org/library/papers/4133497PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/57791

GET https://conductscience.org/api/papers/v1/57791/authors